European Commission logo
español español
CORDIS - Resultados de investigaciones de la UE
CORDIS

2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography Approach

Descripción del proyecto

Tratamiento del cáncer mediante tomografía computarizada

La tomografía computarizada (TAC) es una modalidad de diagnóstico por imagen que combina rayos X para producir imágenes de cualquier parte del cuerpo. El equipo del proyecto PERSEUS, financiado por el Consejo Europeo de Innovación, viene a ampliar la utilidad de la TAC para tratar tumores inaccesibles por otros métodos, como el cáncer de mama triple negativo metastásico y el cáncer de páncreas. PERSEUS tiene previsto implantar un nuevo tratamiento basado en la nanotecnología que utiliza un nanosistema que se activa con el haz de la TAC y provoca la muerte de las células cancerosas mediante calor y especies reactivas del oxígeno. Además, la liberación de antígenos cancerígenos tiene el potencial de activar el sistema inmunitario y generar inmunidad antineoplásica.

Objetivo

PERSEUS intends to implement a novel nanotechnology-based cancer therapy for deep-seated clinically unmanageable, drug-resistant and metastatic tumours. Practical use of nanotechnology in clinical cancer care is still in its infancy with a full potential yet to be realized. The therapy is based on a novel nano-system (NS) made of multifunctional 2D layered nanocrystals. The NS enables, under activation by computed tomography (CT), an effective multimodal therapy with minimal or no adverse effects. This novel paradigm uses CT not to eradicate cancer, but to trigger and to image the NS that locally activates non-mutagenic oncotherapies. The therapies delivered are excited by the conversion of low energy X-rays (i.e. CT) into heat, reactive oxygen species and radiosensitizing agents. X-ray irradiation can also induce immunogenic cell death with the exposure or release of neo-antigens to trigger an anti-cancer immune response.
The use of X-rays makes it possible to reach deep-seated tumours that are inaccessible by visible or near-infrared light-based therapies. In other words, CT is the spark that lights the match. This is a radical vision for an ambitious and high-risk project. The current proposal targets a range of cancer types including metastatic triple negative breast cancer, hepatocellular carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma. The NS is biocompatible and also totally inactive in absence of CT radiation, i.e. the NS becomes active only where the CT beam is delivered so minimizing side effects at distal sites.
The therapy is agnostic to the type of cancer and to gender incidence because it doesn't affect the body biochemistry. This is a second change of paradigm. PERSEUS vision is pursued by a multidisciplinary team composed of physicists, chemists, chemical engineers, biologists, physicians, pharmacologists and radiologists working together to develop an innovative nanotechnological approach to address unmet clinical needs.

Régimen de financiación

EIC - EIC

Coordinador

CONSIGLIO NAZIONALE DELLE RICERCHE
Aportación neta de la UEn
€ 715 125,00
Dirección
PIAZZALE ALDO MORO 7
00185 Roma
Italia

Ver en el mapa

Región
Centro (IT) Lazio Roma
Tipo de actividad
Research Organisations
Enlaces
Coste total
€ 715 125,00

Participantes (5)

Socios (1)